novo glp-1 drug asks FDA to prevent compounders from making knockoffs Blockbuster GLP-1 Diabetes and Weight

4.03 0.12 vs

Enhancing understanding of SEMAs oral formulation in MASLD is necessary, as it may improve compliance and thus lead to better clinical outcomes

Diabetes guidelines recommend these GLP-1 RAs as pharmacologic agents in patients with ASCVD or with high-risk indicators for cardiovascular disease

Conversely, large observational studies have not consistently demonstrated increased gastroparesis incidence compared to other diabetes therapies when accounting for confounding factors

It is important to emphasise that there is no NICE, MHRA or NHS guidance specifically recommending allulose supplementation for patients on GLP-1 therapy

GLP-1 medications like Wegovy and Zepbound have reshaped the weight-loss conversation by helping many people better regulate appetite, feel fuller sooner, and improve blood sugar control